February 2026 monthly summary for pharmaverse/admiralneuro: Delivered a maintenance release (0.2.1) with updated dependencies and documentation. No major bugs fixed this month; focus on stability and upgrade readiness. Impact: improved compatibility for downstream users, clearer release notes, and better onboarding. Skills demonstrated: release management, dependency management, documentation, and collaborative Git workflows.

January 2026: Delivered the ADNV dataset derivation capability from UPSIT neuro test data for pharmaverse/admiralneuro, including a new derivation template, percentile-based calculations, and comprehensive vignette documentation. Updated wordlists and documentation/templates to support reproducible data processing and onboarding.

December 2025: Delivered features and robustness improvements in pharmaverse/admiralneuro, focusing on user experience, clinical scoring capabilities, and code quality. No major bugs fixed this month; changes were accompanied by tests, documentation updates, and lint/style improvements, delivering clear business value and maintainable functionality.

November 2025 monthly summary for pharmaverse repositories focused on delivering API documentation improvements and new neurological datasets, with associated maintenance to improve code readability and CI workflows.

October 2025 brought two high-impact improvements to the pharmaverse/admiralneuro repository: documentation/metadata hardening and a comprehensive code quality refactor aligned with the latest linting standards. These changes reduce onboarding time for developers, improve user-facing docs, and bolster CI reliability and maintainability across the extension.

September 2025 monthly summary for pharmaverse/admiralneuro: Implemented package release readiness and automated versioning, enabling a repeatable and auditable release process. Consolidated release preparation (configuration/document improvements and packaging structure) and established automated version bumps on merges to main (vbump) to ensure consistent versioning and streamlined releases. No major bugs reported this month; minor packaging cleanup completed as part of the release workflow. This work improves release reliability, traceability, and business value by reducing manual overhead and accelerating time-to-market.

Month: 2025-08 — Focused on delivering Centiloid-enabled SUVR analysis, PET data processing automation, data integrity improvements, and documentation updates for the AdmiralNeuro project. These efforts collectively boost processing reproducibility, data quality, and science reach across PET workflows.

In July 2025, delivered enhancements to Centiloid computation and expanded AVID FBB support for the admiralneuro project, along with a critical bug fix to ensure correct data representation. Updated documentation and tests accompany these changes to improve accuracy, reproducibility, and pipeline coverage in neuroimaging analyses. This work strengthens business value by enabling broader use of Centiloid workflows and expanding tracer compatibility across projects.

June 2025 monthly summary for pharmaverse/admiralneuro: Key delivery: a new compute_centiloid function to calculate centiloid values for Amyloid PET imaging, with support for standard calculations (tracer, pipeline, reference region) and optional custom slope/intercept. The release includes thorough input validation, unit tests, and updated documentation, improving reliability and reproducibility of centiloid quantification across studies. Major bugs fixed: None reported this month. Overall impact: standardizes a critical biomarker computation, reduces manual calculation errors, and accelerates downstream analysis. Skills demonstrated: Python function design, robust input validation, test-driven development, and documentation.

April 2025 monthly summary for pharmaverse/admiralneuro. Focused on expanding the SDTM-based neuro data model to support PET tracer data and improving testability and documentation, with clear emphasis on data fidelity, downstream analytics, and reproducibility.

March 2025 monthly summary for pharmaverse/admiralneuro: Delivered a branding refresh by updating favicon assets to reflect the new visual identity across the docs site (pkgdown/favicon). The change improves branding consistency, enhances first impressions on user-facing pages, and supports a coherent market-facing narrative. No major bugs fixed this month. The work demonstrates strong asset management, clear traceability, and alignment between brand guidelines and development workflows, contributing to increased trust and recognition for the project.